3 ms·
A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve the
by gardenfelder 3y ago
A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections